On Demand: The Top 5 Challenges in Immuno-Oncology Trials

In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.

AZ withdraws EU ovarian cancer drug filing

Regulator had "outstanding questions".

Owlstone's breath-based lung cancer diagnostic could save 10...

Trial's next phase will recruit 3,000 patients across 21 international sites.

Stanford and twoXAR strike deal to take on liver cancer

Stanford University School of Medicine is to take on liver cancer by teaming with twoXAR to develop new drug candidates.

Novartis committed to CAR-Ts - but doubts about commercial v...

Novartis may have concerns about commercial prospects, says expert.

Cancer: Localized data leading to real-world care